{"id":"ertapenem-intravenous","safety":{"commonSideEffects":[{"rate":"10-15%","effect":"Diarrhea"},{"rate":"8-12%","effect":"Nausea"},{"rate":"5-8%","effect":"Headache"},{"rate":"5-8%","effect":"Vomiting"},{"rate":"3-5%","effect":"Phlebitis at injection site"},{"rate":"<1%","effect":"Seizures"}]},"_chembl":{"chemblId":"CHEMBL1232","moleculeType":"Small molecule","molecularWeight":"497.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ertapenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall disruption and bacterial death. It has activity against a wide range of gram-positive, gram-negative, and anaerobic bacteria, making it useful for treating complicated intra-abdominal infections, complicated skin infections, and other serious bacterial infections.","oneSentence":"Ertapenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:20.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated intra-abdominal infections"},{"name":"Complicated skin and soft tissue infections"},{"name":"Community-acquired pneumonia"},{"name":"Complicated urinary tract infections"},{"name":"Acute pelvic infections"}]},"trialDetails":[{"nctId":"NCT07376889","phase":"PHASE4","title":"Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia","status":"NOT_YET_RECRUITING","sponsor":"Intermountain Health Care, Inc.","startDate":"2026-02-01","conditions":"Staphylococcus Aureus Bacteremia","enrollment":2096},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05645757","phase":"PHASE1","title":"Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-19","conditions":"Bacterial Infection","enrollment":54},{"nctId":"NCT05896930","phase":"PHASE2","title":"Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2017-11-09","conditions":"Pulmonary Tuberculosis","enrollment":134},{"nctId":"NCT02729116","phase":"PHASE2, PHASE3","title":"Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-07","conditions":"Anti-Infective Agents, Urinary, Escherichia Coli Infections, Klebsiella Infections","enrollment":30},{"nctId":"NCT03218800","phase":"PHASE3","title":"Ertapenem Administered Subcutaneously Versus Intravenously","status":"TERMINATED","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2017-06-01","conditions":"Urinary Tract Infections","enrollment":30},{"nctId":"NCT03788967","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2019-06-03","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":1372},{"nctId":"NCT02724410","phase":"NA","title":"Role of Intravenous Versus Home Oral Antibiotics in Perforated Appendicitis","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2011-01","conditions":"Perforated Appendicitis","enrollment":82},{"nctId":"NCT04748120","phase":"NA","title":"Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-12-28","conditions":"Covid19, Appendicitis, Cholecystitis, Acute","enrollment":2},{"nctId":"NCT05255575","phase":"","title":"A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2018-03-01","conditions":"Hidradenitis Suppurativa","enrollment":""},{"nctId":"NCT03032510","phase":"PHASE3","title":"Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Tetraphase Pharmaceuticals, Inc","startDate":"2017-01","conditions":"Complicated Urinary Tract Infections","enrollment":1205},{"nctId":"NCT03236961","phase":"NA","title":"Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Turku University Hospital","startDate":"2017-04-03","conditions":"Acute Appendicitis","enrollment":552},{"nctId":"NCT03234296","phase":"NA","title":"Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis","status":"ENROLLING_BY_INVITATION","sponsor":"Turku University Hospital","startDate":"2017-08-09","conditions":"Acute Appendicitis","enrollment":147},{"nctId":"NCT04505683","phase":"PHASE2, PHASE3","title":"A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2018-12-13","conditions":"Complicated Urinary Tract Infection Including Acute Pyelonephritis","enrollment":112},{"nctId":"NCT03080103","phase":"","title":"Appendectomy Versus Conservative Treatment for Uncomplicated Acute Appendicitis","status":"COMPLETED","sponsor":"Mauro Podda","startDate":"2017-06-01","conditions":"Acute Appendicitis, Appendicitis Recurrent, Appendectomy","enrollment":300},{"nctId":"NCT01723150","phase":"PHASE4","title":"Antibiotics for Klebsiella Liver Abscess Study","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2013-11-05","conditions":"Liver Abscess, Pyogenic","enrollment":152},{"nctId":"NCT01370616","phase":"PHASE3","title":"Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-02","conditions":"Infection; Diabetic Foot","enrollment":565},{"nctId":"NCT01069900","phase":"PHASE3","title":"Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07-21","conditions":"Intraabdominal Infections","enrollment":458},{"nctId":"NCT02505386","phase":"PHASE4","title":"Pharmacokinetics of Ertapenem in Patients Aged Over 75","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-08","conditions":"Infections","enrollment":27},{"nctId":"NCT02789865","phase":"PHASE2","title":"Clinical Trial Comparing ERAT vs Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-05","conditions":"Acute Appendicitis","enrollment":240},{"nctId":"NCT02537847","phase":"PHASE2","title":"Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-11","conditions":"Infection Due to Escherichia Coli, Acute Pyelonephritis","enrollment":96},{"nctId":"NCT01587495","phase":"PHASE1","title":"Pharmacokinetics and Safety of Ertapenem in the Postpartum Period","status":"TERMINATED","sponsor":"Daniel Benjamin","startDate":"2012-03","conditions":"Endometritis","enrollment":3},{"nctId":"NCT00492726","phase":"PHASE3","title":"Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Infection","enrollment":804},{"nctId":"NCT01497990","phase":"PHASE4","title":"Pharmacokinetics Ertapenem Burns","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2010-01","conditions":"Burn Patients","enrollment":8},{"nctId":"NCT01148771","phase":"PHASE4","title":"Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2010-08","conditions":"Healthy","enrollment":12},{"nctId":"NCT01159379","phase":"PHASE4","title":"Safety of Ertapenem in Beta-lactam Allergic Patients.","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2011-01","conditions":"IgE-Mediated Hypersensitivity, Allergy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":195,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ertapenem intravenous","genericName":"Ertapenem intravenous","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ertapenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Complicated intra-abdominal infections, Complicated skin and soft tissue infections, Community-acquired pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}